Does autonomous macrophage-driven inflammation promote alveolar damage in COVID-19?

Eur Respir J. 2022 Dec 1;60(6):2201521. doi: 10.1183/13993003.01521-2022. Print 2022 Dec.

Abstract

SARS-CoV-2 has caused devastating effects with over 550 million infections by July 2022 and approximately 6.4 million deaths [1]. Societal and economic impacts will reverberate for years, with continuous evolution of SARS-CoV-2 as it persistently spreads through the human population as exemplified by reduced activity of vaccines and monoclonals against Omicron BA.4 or BA.5 subvariants [2]. A greater understanding of pathogenesis and more tailored therapeutic approaches are therefore essential.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • COVID-19*
  • Humans
  • Inflammation
  • Lung
  • Macrophages
  • Permissiveness
  • SARS-CoV-2*

Substances

  • Angiotensin-Converting Enzyme 2